Skip to main content
HONZ PHARMACEUTICAL CO., LTD. logo

HONZ PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 300086 ISIN · CNE100000QM6 LEI · 300300SA7ZULJ816T861 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,012 across all filing types
Latest filing 2021-04-23 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300086

About HONZ PHARMACEUTICAL CO., LTD.

https://www.honz.com.cn

HONZ Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and marketing of pharmaceutical products, with a specialized emphasis on pediatric healthcare. The company provides a diverse range of medications specifically formulated for children, including antipyretics, analgesics, respiratory treatments, and anti-infective agents. It utilizes advanced drug delivery systems and taste-masking technologies to enhance patient compliance and therapeutic efficacy. In addition to its pediatric portfolio, the organization produces various chemical drugs and traditional Chinese medicine preparations. The company maintains multiple production bases and research centers dedicated to advancing clinical solutions and ensuring high standards of product quality across its therapeutic categories.

Recent filings

Filing Released Lang Actions
关于2020年计提资产减值准备的公告
Audit Report / Information Classification · 95% confidence The document is an announcement from 康芝药业股份有限公司 regarding the 2020 fiscal year asset impairment provisions. It details the reasons, scope, and amounts of asset impairment provisions, including credit impairment losses, inventory write-downs, long-term equity investment impairment, and construction in progress impairment. The document also explains the accounting policies and methods used for impairment testing and provisioning. It states that the impairment provision reduces the 2020 consolidated profit and has been audited by an accounting firm. The document is a formal announcement of the impairment provision decision and its financial impact, but it does not contain a full annual report or comprehensive financial statements. It is not a full audit report but includes audit confirmation of the impairment provision. The document is more detailed than a simple regulatory filing but does not constitute a full annual report or interim report. Given the detailed accounting and audit confirmation of impairment provisions, this fits best under Audit Report / Information (AR), which covers standalone audit reports and applied accounting principles related to asset impairment and internal assessments, excluding full annual reports. FY 2020
2021-04-23 Chinese
公司2020年度财务决算报告
Annual Report Classification · 95% confidence The document is titled '2020 年度财务决算报告' which translates to '2020 Annual Financial Settlement Report'. It includes detailed financial statements such as balance sheet, income statement, cash flow statement, and notes, audited by an accounting firm with an audit opinion. The document contains comprehensive financial data for the full fiscal year 2020, including assets, liabilities, equity, revenues, profits, and various financial ratios. The presence of audited financial statements and full-year financial performance indicates this is an Annual Report. The document length is 2575 characters, which is relatively short but contains substantive financial data, not just an announcement or certification. Therefore, it fits the definition of an Annual Report (10-K). FY 2020
2021-04-23 Chinese
董事会决议公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 13th meeting of the 5th Board of Directors of 康芝药业股份有限公司, held on April 22, 2021. It includes approvals of the 2020 annual board work report, president's work report, 2020 annual report and summary, 2020 financial final accounts report, profit distribution plan, fundraising usage report, internal control self-evaluation report, daily related party transactions plan, investor relations management plan, social responsibility report, and a proposal for applying for a comprehensive credit line. The document repeatedly states that these reports and plans are available on the official disclosure website (巨潮资讯网) and that the resolutions will be submitted to the 2020 annual shareholders meeting for approval. The document itself does not contain the full annual report or financial statements but is a formal announcement of board meeting decisions and approvals related to the annual report and other reports. The document length is 4134 characters, which is relatively short and mainly summarizes meeting resolutions and references other detailed reports available elsewhere. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement of board meeting resolutions and report approvals, not the full Annual Report (10-K) or other full reports themselves.
2021-04-23 Chinese
2020年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as the "2020 年年度报告摘要" which translates to "2020 Annual Report Summary". It contains detailed company information, business overview, financial data for multiple years, quarterly financial indicators, shareholder information, and discussion of business operations and development. The presence of audited financial data, management discussion, and comprehensive business description aligns with the characteristics of an Annual Report. The document length is substantial (15,000 characters), and it is not merely an announcement or a brief summary but contains substantive financial and operational data. Therefore, it fits the definition of an Annual Report (10-K). FY 2020
2021-04-23 Chinese
康芝药业股份有限公司第一期员工持股计划（2021年第一次修订）
Board/Management Information Classification · 95% confidence The document is a detailed plan regarding an employee stock ownership plan (员工持股计划) for 康芝药业股份有限公司. It includes legal references, funding sources, management structure, rights and obligations of participants, lock-up periods, and procedures for approval by the board and shareholders. It is a comprehensive internal governance and operational document related to the employee stock ownership plan, not a financial report, earnings release, or announcement of voting results. It does not fit into categories like Annual Report, Earnings Release, or Voting Results. It is primarily about the governance and management of the employee stock ownership plan, including board and management roles, rights, and procedures. Therefore, the best fitting category is Board/Management Information (MANG), as it relates to management decisions and governance of the employee stock ownership plan.
2021-04-02 Chinese
第五届董事会第十二次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of a board meeting resolution by 康芝药业股份有限公司 (Kangzhi Pharmaceutical Co., Ltd.) regarding the revision of the company's first employee stock ownership plan. It details the board meeting date, attendance, voting results, and references to related legal opinions and disclosures on the official information disclosure website. The document does not contain financial statements or detailed financial data, nor is it a full report. It is a formal announcement of a board decision related to employee stock plans, which is a management/board information update. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length is short (1078 characters), and it is not a report publication announcement or regulatory filing. Hence, the classification is MANG with high confidence.
2021-04-02 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.